|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2009-10-16 |
An open label, Balanced, Randomized, Active control clinical trial to compare Safety and Efficacy of Risorine Capsule in adult patients with RNTCP Category I Pulmonary Tuberculosis
TO STUDY EFFECT OF RISORINE THERAPY ON PLASMA RIFAMPICIN LEVELS IN PATIENTS WHO REMAIN SPUTUM POSITIVE AT THE END OF 8 WEEKS OF CONVENTIONAL INTENSIVE PHASE THERAPY
Efficacy and Safety Study of Risorine (FDC of Rifampicin 200mg + Isoniazid 300mg + Piperine 10mg) in Patients with Newly Diagnosed Sputum Smear Positive Pulmonary Tuberculosis: a Randomized, Single-blind, Comparative Clinical Trial
100 项与 CYP3A x P-gp x RNAP 相关的临床结果
100 项与 CYP3A x P-gp x RNAP 相关的转化医学
0 项与 CYP3A x P-gp x RNAP 相关的专利(医药)